| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 19 securities · passive | ||||||
|
Verrica Pharmaceuticals Inc.
13G/A
VRCA · 92511W207
|
4.99% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 4.99% | |||||
| Michael Cho | 4.99% | |||||
|
NextCure, Inc.
13G/A
NXTC · 65343E207
|
10.0% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 10.0% | |||||
| Michael Cho | 10.0% | |||||
|
Lexeo Therapeutics, Inc.
13G/A
LXEO · 52886X107
|
9.8% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 9.8% | |||||
| Michael Cho | 9.8% | |||||
|
Karyopharm Therapeutics Inc.
13G/A
KPTI · 48576U205
|
6.5% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 6.5% | |||||
| Michael Cho | 6.5% | |||||
|
Helix Acquisition Corp. III
13G/A
HLXC · G4444S107
|
4.8% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 3.5% | |||||
| Michael Cho | 4.8% | |||||
|
Forte Biosciences, Inc.
13G/A
FBRX · 34962G208
|
0% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 0% | |||||
| Michael Cho | 0% | |||||
|
Equillium, Inc.
13G/A
EQ · 29446K106
|
4.1% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 4.1% | |||||
| Michael Cho | 4.1% | |||||
|
Amanat Acquisition Corp.
13G/A
AMAN · G0375M101
|
4.8% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 4.8% | |||||
| Michael Cho | 4.8% | |||||
|
Jasper Therapeutics, Inc.
13G
JSPR · 471871202
|
5.6% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 5.6% | |||||
| Michael Cho | 5.6% | |||||
|
Research Alliance Corporation III
13G
RACC · G75226103
|
9.5% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 9.5% | |||||
| Michael Cho | 9.5% | |||||
|
Vogenx, Inc.
13G
VOGX · 92859A106
|
6.2% |
11/13/2026
Event 9/30/2026
|
||||
| Affinity Asset Advisors, LLC | 6.2% | |||||
| Michael Cho | 6.2% | |||||
|
First Tracks Biotherapeutics, Inc
13G
TRAX · 337185102
|
5.8% |
8/13/2026
Event 6/30/2026
|
||||
| Affinity Asset Advisors, LLC | 5.8% | |||||
| Michael Cho | 5.8% | |||||
|
Ovid Therapeutics Inc.
13G/A
OVID · 690469101
|
7.9% |
8/13/2026
Event 6/30/2026
|
||||
| Affinity Asset Advisors, LLC | 7.9% | |||||
| Michael Cho | 7.9% | |||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
5.5% |
8/13/2026
Event 6/30/2026
|
||||
| Affinity Asset Advisors, LLC | 5.5% | |||||
| Michael Cho | 5.5% | |||||
|
iBio, Inc.
13G/A
IBIO · 451033708
|
10.0% |
8/13/2026
Event 6/30/2026
|
||||
| Affinity Asset Advisors, LLC | 10.0% | |||||
| Michael Cho | 10.0% | |||||
|
Ventyx Bioscience, Inc.
13G/A
VTYX · 92332V107
|
0% |
5/14/2026
Event 3/31/2026
|
||||
| Affinity Asset Advisors, LLC | 0% | |||||
| Michael Cho | 0% | |||||
|
Sutro Biopharma, Inc.
13G/A
STRO · 869367201
|
6.5% |
5/14/2026
Event 3/31/2026
|
||||
| Affinity Asset Advisors, LLC | 6.5% | |||||
| Michael Cho | 6.5% | |||||
|
Sutro Biopharma, Inc.
13G
STRO · 869367102
|
7.8% |
10/23/2025
Event 10/16/2025
|
||||
| Affinity Healthcare Fund, LP | 7.8% | |||||
| Affinity Asset Advisors, LLC | 7.8% | |||||
|
Inozyme Pharma, Inc.
13G/A
INZY · 45790W108
|
2.9% |
5/30/2025
Event 5/20/2025
|
||||
| Affinity Healthcare Fund, LP | 2.9% | |||||
| Affinity Asset Advisors, LLC | 2.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.